Advertisements

Мебеверин

Quick links to important sections

Мебеверин

Advertisements
Advertisements

Treatment option: Pain, Biliary Colic, Colic

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Мебеверин

Mebeverine: Definition and Pharmacological Classification

Property Description
Active ingredient Mebeverine hydrochloride
Form Oral preparations (e.g., tablet, prolonged-release capsule)
Pharmacological class Musculotropic antispasmodic
Common use Relief of intestinal cramping and spasm
Origin Synthetic

Mebeverine is a synthetic spasmolytic compound whose active substance is Mebeverine hydrochloride. It is formally classified as a musculotropic antispasmodic, a specific class of medicine designed to act directly on the muscle tissue of the gut wall. This classification is recognized for its targeted effect, distinguishing Mebeverine because its action is localized and selective, achieving relaxation without broadly involving the body's general nervous system or anticholinergic pathways. This characteristic is a key differentiating factor from older, less specific antispasmodic agents. This focused approach provides a targeted method for managing gut hyperactivity, which is often the source of painful cramping and discomfort.


Composition, Form, and General Therapeutic Purpose

Mebeverine is typically a single-ingredient product commonly provided as an oral preparation, available in forms such as a standard tablet or, more frequently, a prolonged-release capsule. The prolonged-release capsule is a formulation designed to slowly release the Mebeverine hydrochloride over an extended period. This mechanism helps to sustain the drug's effect and maintain a consistent level of selective smooth muscle relaxation over many hours, benefiting patients who require persistent relief throughout the day. Mebeverine is utilized for the symptomatic treatment of abdominal pain and gut motility disorders. The preparation's general therapeutic purpose is to mitigate the excessive muscle contraction, or spasm, that occurs in the gastrointestinal tract, thereby promoting a more comfortable and normalized state of internal muscle function.

Regulatory References

  1. EMA
Advertisements

What side effects are possible with Мебеверин?

Possible side effects and safety information

The official regulatory safety profile for Mebeverine focuses primarily on documented hypersensitivity reactions and specific population restrictions.


Official Adverse Reactions and Frequency

The adverse reactions documented in regulatory sources are classified according to the standard System-Organ Class (SOC) categories. All reported adverse effects are categorized with an official frequency of Not known, meaning the frequency cannot be precisely estimated from the available spontaneous postmarketing reporting data.

System-Organ Class (SOC) Documented Reactions
Immune System Disorders Hypersensitivity (including anaphylactic reaction)
Skin and Subcutaneous Tissue Disorders Urticaria (hives), Angioedema, Exanthema (rash), Face Oedema (swelling)

Serious manifestations of the documented hypersensitivity include the risk of a severe allergic response, such as an anaphylactic reaction.


Population-Specific Safety Statements

Official labeling contains specific restrictions regarding the use of Mebeverine in certain populations:

  • Pregnancy and Breast-feeding: Use is not recommended during pregnancy and should be avoided during breast-feeding, as the safety and excretion into human milk are not sufficiently established by regulatory data.
  • Paediatric Population: Mebeverine is not recommended for use in children and adolescents below 18 years of age due to a lack of sufficient data on safety and efficacy in this age group.

Safety Restrictions

Mebeverine is formally contraindicated in individuals with a known hypersensitivity to mebeverine hydrochloride or to any of the product's excipients. Additionally, formulations containing lactose carry restrictions for patients with rare hereditary issues like galactose intolerance or glucose-galactose malabsorption.

Advertisements

Overdose and Emergency Response

Mebeverine Overdose and When to Seek Help

The official regulatory classification of Mebeverine overdose is based on documented clinical experience, which indicates that symptoms are typically absent or mild and rapidly reversible. When manifestations are observed, they have been categorized as being of a neurological nature and a cardiovascular nature. Though effects are generally mild, regulatory documentation advises that CNS excitability is a theoretically predicted outcome that may occur.

Immediate Emergency Actions

It is a regulatory mandate that individuals must seek immediate medical attention or go to a hospital straight away if an overdose is suspected. This ensures the patient receives professional assessment and necessary symptomatic treatment.

Management Procedures

Official documentation confirms that no specific antidote is known for Mebeverine overdose. Management focuses on support, with symptomatic treatment being recommended. Gastric lavage may be considered only under very specific circumstances, such as in cases of multiple intoxication or when the ingestion is discovered within about one hour. Furthermore, absorption reducing measures are not considered necessary.

Population Considerations

Post-marketing data reviewed by regulatory authorities indicate that no specific overdose risk could be identified for elderly, renal impaired, or hepatic impaired patients. This suggests that these populations do not present a distinct severity concern in the context of overdose when compared to the general population.

Advertisements

Therapeutic Uses of Мебеверин

Main Uses and Therapeutic Focus

Mebeverine is a specialized antispasmodic medication primarily used to manage functional gastrointestinal disorders. Its therapeutic action is focused on the smooth muscles of the digestive tract, particularly in the lower intestine and colon.

Irritable Bowel Syndrome (IBS)

The primary application of Mebeverine is the symptomatic relief of Irritable Bowel Syndrome. It is used to address a range of discomforts associated with this condition, including:

  • Abdominal Pain and Cramps: It helps relax the intestinal muscles to alleviate sharp or persistent pain.
  • Bloating and Distension: By regulating muscle contractions, it can assist in reducing the sensation of fullness and visible swelling in the abdomen.
  • Altered Bowel Habits: It is utilized to manage the persistent diarrhea or constipation (or alternating patterns of both) often found in IBS patients.

Other Functional Digestive Disorders

Beyond IBS, Mebeverine may be used to treat similar symptoms resulting from other functional disturbances of the gastrointestinal tract. These include:

  • Chronic Irritable Colon: Management of long-term discomfort and irregular motility in the large intestine.
  • Spastic Constipation: Relief of constipation caused by excessive muscle tension in the gut wall.
  • Mucous Colitis: Addressing abdominal distress in conditions characterized by inflammation-like symptoms without a primary infectious cause.

Core Benefits

The benefit of Mebeverine lies in its selective action. Unlike some other medications that affect the autonomic nervous system, Mebeverine acts directly on the smooth muscle cells of the gut. This approach offers several advantages in a clinical context:

  • Targeted Relief: It works specifically where the discomfort originates in the digestive system.
  • Preservation of Normal Motility: At therapeutic levels, it aims to reduce painful spasms without completely stopping the natural movement (peristalsis) required for healthy digestion.
  • Reduced Systemic Impact: Because it does not rely on anticholinergic mechanisms, it avoids many common side effects associated with broader-acting antispasmodics, such as dry mouth or blurred vision.
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Mebeverine?

The population eligibility for mebeverine is defined by regulatory bodies through specific contraindications and restrictions, primarily establishing adults as the standard approved user group.

Absolute Contraindications

Mebeverine is contraindicated in patients with known hypersensitivity to the active substance, mebeverine hydrochloride, or to any excipients in the specific formulation. Certain formulations containing lactose or sucrose are also contraindicated for individuals with rare hereditary intolerances, such as galactose intolerance or sucrase-isomaltase insufficiency.

Age-Related and Conditional Restrictions

Population Group Regulatory Status
Children and Adolescents (under 18) Not Recommended (Due to insufficient safety and efficacy data)
Pregnancy Not Recommended (Limited human data)
Breastfeeding Not Recommended (Unknown excretion into breast milk)
Older Adults No specific dose adjustment is necessary
Renal/Hepatic Impairment Caution advised in advanced disease

Use in the pediatric population is formally not recommended because safety and efficacy have not been sufficiently established in children and adolescents below 18 years. Use during pregnancy and breastfeeding is also not recommended due to limited or unknown data on potential exposure.

Advertisements

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Mebeverine

The official regulatory profile for mebeverine hydrochloride is defined by the lack of known interactions with co-administered medicinal products. This structure is based on the authoritative regulatory statements found in the Summary of Product Characteristics (SmPC) documentation.


Interaction Scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions None documented. The official labeling states that no interactions with other medicines are known.
Specific interacting medicines (if explicitly listed) None listed. No specific pharmaceutical products are listed in official labeling as having known interactions with mebeverine hydrochloride.
Timing-based interaction rules (if applicable) None documented. There are no mandatory rules requiring the spacing of mebeverine administration from other medicinal products by a specific duration.
Interaction-related restrictions Alcohol (Ethanol): No Interaction. Studies have specifically demonstrated the absence of any interaction between mebeverine hydrochloride and ethanol (alcohol).

Interaction Classifications (High-Level)

Classification Official Regulatory Documentation
Interaction severity classification Not Classified. No interactions are classified by severity because no interactions with other medicines are known.
Interaction-context constraints The interaction profile is constrained by the regulatory statement that no interaction studies have been performed, with the exception of alcohol.

Connection to the overall interaction profile (3 sentences): The regulatory interaction structure is primarily characterized by the absence of documented findings and the lack of clinically relevant pharmacokinetic or pharmacodynamic interactions with other medicinal products. This results in the lack of formally prohibited co-administrations or timing constraints. The only specific finding noted in the official regulatory documentation is the established absence of interaction with alcohol.

Advertisements

Mechanism of Action

️ How Mebeverine Works


Direct Control of Intestinal Smooth Muscle Excitability

This key domain centers on the molecule’s ability to act as a musculotropic agent by directly targeting the smooth muscle cells of the gut wall. The primary mechanism involves inhibiting the influx of ions, specifically blocking Voltage-Operated Calcium Channels (VOCCs) and Sodium Channels. By limiting the entry of these crucial signaling ions, the molecule suppresses the electrical signals needed for the muscle to sustain an excessive contraction, resulting in a reduction in smooth muscle tone. This action is highly localized and selective, primarily targeting the mechanisms of hypercontractility rather than the pathways regulating basal motility.


Localized Reduction of Membrane Excitability

A secondary domain involves the reduction of membrane excitability in the muscle cells and local nerve endings, a physiological effect attributed to Na^+ channel modulation. This is augmented by minor modulation of local regulatory systems, including a weak antagonism at muscarinic receptors and inhibition of phosphodiesterase. These combined peripheral effects decrease the sensitivity of the gut wall to external stimuli, augmenting the primary action by dampening electrical excitability and modulating the molecular signals for hypercontraction.


Mechanistic Specificity and Constraints

The drug's mechanism is defined by its peripheral, non-anticholinergic action focused on modulating hypercontractility by reducing cellular excitability. This specific mode of action distinguishes it from mechanisms involving broad systemic nervous system blockade. The mechanistic effect is primarily constrained to influencing functional muscle over-activity and is less relevant or constrained by biological processes associated with structural changes or organic disease.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Mebeverine

This section outlines the usage instructions for Mebeverine (Mebeverine Hydrochloride), focusing on administration logistics and dosing schedules.


Dosage and Administration

Mebeverine is strictly for oral use and is available primarily in two forms with corresponding standard regimens:

Dosage Form & Strength Standard Adult Dosing Frequency
Film-coated Tablet (135 mg) One tablet Three times a day
Modified-Release Capsule (200 mg) One capsule Twice a day

Administration Conditions

Condition Instruction
Timing with Meals Take approximately 20 minutes before a meal.
Intake Method Tablets and capsules must be swallowed whole with a glass of water. Do not crush, chew, or break them, as this may disrupt the intended modified-release mechanism or affect the taste.

Procedural Rules

  • Missed Dose: If a dose is missed, do not take a double dose to compensate. Continue with the next scheduled dose at the usual time.
  • Dose Adjustment: Following several weeks of symptom control, the total daily dosage may be gradually reduced.
  • Age Restriction: The 135 mg tablets and 200 mg capsules are not recommended for use in children and adolescents under 18 years due to insufficient safety and efficacy data.

These instructions define the standardized protocol for the correct administration of Mebeverine.

Advertisements

Recent Clinical Evidence

Мебеверин: Recent Clinical Evidence

This overview summarizes the formal research describing the clinical evaluation of Mebeverine, focusing on the types of studies conducted and the recognized evidence gaps, as reported in authoritative scientific sources. This information is purely descriptive and does not offer treatment recommendations or clinical guidance.


Evidence for Symptomatic Management of Irritable Bowel Syndrome (IBS)

The primary clinical research focused on the use of mebeverine in the symptomatic management of Irritable Bowel Syndrome (IBS). The evidence base consists of Randomized Controlled Trials (RCTs) and meta-analyses that pool data from various clinical studies. Research examined patient-reported outcomes describing perceived discomfort, focusing on the severity and frequency of abdominal pain and cramping.

Studies report how symptoms evolved in the observed populations. Findings related to symptom change often showed variability when compared to placebo. Evidence quality varies across studies, contributing to the consensus that the overall evidence level is moderate.


Long-term Follow-up and Special Populations

Research exploring symptom changes typically defined its study periods over short-term or intermediate-term intervals. Evidence for long-term outcomes is not fully established by the core controlled trial data, and data are limited regarding the sustained monitoring of symptoms over extended study periods.

Mebeverine was primarily studied in adult patients, though it was evaluated in populations such as adolescents and children with symptoms consistent with the study inclusion criteria. Data for certain groups remain insufficient, and research descriptions related to the elderly are often sourced from smaller study groups rather than large-scale dedicated RCTs.


What is Still Uncertain

The existing evidence quality varies across studies, and findings were mixed regarding certain measured outcomes. For instance, research describes studies focusing on outcomes related to physical discomfort, but its association with the normalization of bowel habits in defined IBS subtypes was observed to be inconsistent. The key limitation remains the lack of extensive comparative evidence against other compounds and the limited information on long-term outcomes.

Key Studies & References

  1. Public Assessment Report Scientific discussion Mebeverine Aristo 200 mg modified release capsules, hard (mebeverine hydrochloride)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Мебеверин (FAQ)


Q: How quickly does Мебеверин usually start relieving symptoms?

Clinical information suggests Mebeverine may start to provide symptom relief within approximately one hour of administration. This timing is consistent with its targeted action on gut muscle spasms.

Q: Can Мебеверин be taken on an empty stomach?

The official administration instructions recommend taking Mebeverine about 20 minutes before a meal. Following this guidance helps ensure the medicine works as intended. It is important to follow the specific timing instructions provided by your prescribing healthcare professional.

Q: What happens if you forget to take a dose of Мебеверин?

If a dose is missed, regulatory guidance states that a double dose should not be taken to compensate for the forgotten one. The procedure is to simply skip the missed dose and continue with the next scheduled dose at the usual time.

Q: Does Мебеверин affect driving ability or alertness?

Official patient information states that Mebeverine is generally not expected to affect one's ability to drive or operate machinery. However, individuals experiencing side effects such as dizziness or tiredness should use caution when operating machinery or driving.

Q: Can Мебеверин help with general stomach cramping, not just IBS?

Mebeverine’s primary therapeutic indication is the symptomatic treatment of abdominal pain and cramping associated with Irritable Bowel Syndrome (IBS). It is also indicated for treating gastrointestinal spasms that occur secondary to other underlying organic diseases.

Q: Is Мебеверин known to interact with commonly used over-the-counter pain relievers?

Regulatory product information indicates that no known interactions have been reported with common over-the-counter painkillers. This includes common medicines such as paracetamol (acetaminophen) and ibuprofen.

Q: Is it normal to feel a little dizzy or tired after taking Мебеверин?

Dizziness and mild tiredness have been reported as side effects in post-marketing reports for Mebeverine. These effects are usually mild and short-lived. If these effects persist or cause concern, professional guidance should be sought.

Q: Are there different forms of Мебеверин (e.g., tablets, capsules, extended-release)?

Yes, Mebeverine is commonly available in two main forms: the standard film-coated tablet and a modified-release (or slow-release) capsule. The modified-release form is specifically designed to slowly release the medicine over an extended period.

Q: Why is Мебеверин sometimes prescribed for biliary colic?

Mebeverine is indicated for the treatment of gastrointestinal spasm secondary to various organic diseases. Since biliary colic (pain from the gallbladder) involves the spasm of smooth muscle, Mebeverine may be used for its spasmolytic effect.

Q: Does Мебеверин affect blood pressure?

The documented side effect profile does not specifically list effects on blood pressure. Mebeverine’s mechanism of action is focused on the smooth muscle of the gut and is not known to generally affect systemic blood pressure.

Q: Are there any specific foods to avoid while taking Мебеверин?

Official regulatory documents and patient information do not list any specific foods that need to be avoided while undergoing treatment with Mebeverine.

Q: What should I do if the side effects of Мебеверин are bothersome but not severe?

If less serious side effects are bothersome, it is advisable to consult a pharmacist or doctor for specific guidance on managing the symptoms.

Q: Does Мебеверин interact with common anxiety or depression medications?

According to the official product information, no interactions are known between Mebeverine and other medicines. There are no formally prohibited co-administrations listed, including for common anxiety or depression medications.

Q: Why do some people experience constipation when taking Мебеверин?

Constipation has been reported as a documented side effect, meaning it may occur in some individuals taking Mebeverine. If constipation becomes severe or persistent, guidance from a healthcare provider should be sought.

Q: Can Мебеверин be taken with oral contraceptives?

The official regulatory profile indicates that no known interactions with other medicinal products exist for Mebeverine. Therefore, there are no formally prohibited co-administrations listed, including with oral contraceptives.

Q: Are there any known severe but rare side effects of Мебеверин I should know about?

The serious adverse effects that have been reported are primarily related to hypersensitivity (severe allergic reaction). These may include symptoms like swelling of the face, neck, or tongue (angioedema), or difficulty breathing (anaphylactic reaction).

Q: Is there a generic version of Мебеверин, and how does it compare?

Mebeverine hydrochloride is the active ingredient and is available as a generic drug internationally under many different brand names. Generic products contain the same active ingredient. These products must meet the regulatory standards for quality and content required by health authorities.

Q: Can people with kidney problems use Мебеверин?

Official guidance advises caution for individuals with advanced kidney disease. This is because the body relies on the kidneys to excrete the drug’s breakdown products. Professional guidance should be sought if you have kidney problems.

Q: Does Мебеверин cause dry mouth?

Mebeverine is classified as a musculotropic antispasmodic and is not anticholinergic. Dry mouth is not listed as a commonly documented side effect, as the medicine acts directly on the muscle and avoids broad anticholinergic effects.

Q: Why is Мебеверин sometimes referred to as a 'local' antispasmodic?

Mebeverine is described as having a direct and localized action on the smooth muscle of the gastrointestinal tract. This means its effect is focused on the gut, and it does not block the nervous system or cause broad systemic anticholinergic effects, which distinguishes it from other types of antispasmodics.

Q: Does Мебеверин interact with herbal supplements like St. John's Wort?

The official product information states that no interactions with other medicinal products are known. There are no formally prohibited co-administrations listed, including for common herbal supplements.

Q: Is Мебеверин only for diarrhea-dominant IBS, or all types?

Mebeverine is indicated for the symptomatic relief of abdominal pain and spasms associated with Irritable Bowel Syndrome. This indication covers the management of these key symptoms across the different subtypes of IBS.

Q: What are the official warnings about combining Мебеверин with other gut medications?

The regulatory profile indicates no known interactions with other medicines. However, because Mebeverine targets gut spasm, combining it with other spasm-relieving remedies is generally discouraged, as it may not provide additional benefit.

Q: Why are there different doses of Мебеверин available?

The two common doses (e.g., tablets and capsules) exist because the modified-release capsule formulation is designed to release the medicine slowly. This allows it to maintain its effect over a longer period, resulting in less frequent required administration.

Q: Does Мебеверин interact with common blood thinners?

The official regulatory documentation states that no interactions with other medicinal products are known. There are no formally prohibited co-administrations listed, including with common blood thinners.

Q: Can you take Мебеверин if you are sensitive to lactose?

Formulations of Mebeverine that contain lactose carry a restriction for patients with rare hereditary issues, such as galactose intolerance or glucose-galactose malabsorption. Individuals with lactose sensitivity should check the ingredient list of their specific Mebeverine formulation.

Q: Has Мебеверин been studied for use in children under 12?

Mebeverine is formally not recommended for use in children and adolescents below the age of 18. This restriction is due to insufficient data being available to establish its safety and effectiveness in this specific age group.

Advertisements

How should Мебеверин be stored and disposed of?

Official Storage and Disposal Requirements

Mebeverine must be stored strictly according to the conditions detailed in the official regulatory labeling.

Storage Requirement Condition
Maximum Temperature Do not store above 30 C or Store below 30 C
Environmental Protection Store in a dry place; Protect from light; Keep in original package to protect from moisture
Child Safety Keep medicine out of the sight and reach of children

Storage of the medicine outside these limits may compromise its stability, particularly after the printed expiry date. For disposal, regulatory guidance mandates that Mebeverine must not be thrown away with wastewater or household waste to help protect the environment. Any unused or expired product should be disposed of by consulting a pharmacist or following local requirements for the collection of medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Мебеверин found in:

A-Z Index: